Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGENGet Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

Shares of OGEN opened at $1.67 on Tuesday. The company’s fifty day simple moving average is $1.55. The firm has a market capitalization of $7.49 million, a price-to-earnings ratio of -0.20 and a beta of 0.57. Oragenics has a one year low of $1.00 and a one year high of $7.74.

Oragenics (NYSE:OGENGet Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in Oragenics, Inc. (NYSE:OGENFree Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by institutional investors and hedge funds.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Recommended Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.